Loading…
VYKAT XR is a prescription medicine and the first and only FDA-approved treatment for hyperphagia in people aged 4 years and older with Prader-Willi syndrome (PWS). It is intended to reduce extreme hunger and persistent thoughts about food in PWS, with resources for patients and healthcare professionals on what to expect. Safety information highlights risks such as hyperglycemia and potential diabetic ketoacidosis, requiring monitoring of blood sugar (HbA1c) and possible dose adjustments or discontinuation by a clinician.
AI named VYKAT XR from January 2026 to March 2026.